Rectifying defects in tumor vasculature to improve chemo- and radiation therapies

纠正肿瘤血管系统缺陷以改善化疗和放射治疗

• 批准号: 7766926
• 负责人: DONALD R SENGER
• 金额: $ 35.28万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-03-14 至 2013-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7766926
• 关键词: Architecture; Blood Vessels; Blood flow; Calpain; Cancer Patient; Cancerous; Clinical; Clinical Research; Cytoskeleton; Cytotoxic agent; Defect; Development; Disease; Dose; Drug Combinations; Drug Delivery Systems; Drug Design; Effectiveness; Elements; Endothelial Cells; Exhibits; Family; Goals; Guanosine Triphosphate Phosphohydrolases; Hypoxia; Lead; Link; Malignant Neoplasms; Measures; Mediating; Modeling; Morphogenesis; Neoplasms in Vascular Tissue; Outcome; Oxygen; Patients; Peptide Hydrolases; Perfusion; Pharmaceutical Preparations; Phenotype; Radiation therapy; Reaction Time; Research; Scheme; Signal Pathway; Solid Neoplasm; Testing; Therapeutic; Time; Tumor Angiogenesis; Tumor Oxygenation; Tumor-Associated Vasculature; Validation; Work; antiangiogenesis therapy; cancer therapy; chemotherapeutic agent; chemotherapy; design; drug development; efficacy testing; improved; killings; mouse model; neovasculature; novel strategies; outcome forecast; preclinical study; public health relevance; research study; response; rho; rho GTP-Binding Proteins; tumor; tumor progression; vessel regression

DESCRIPTION (provided by applicant): The vasculature of solid tumors is highly defective, resulting in poor blood flow and hypoxia. These defects have profoundly negative consequences for the delivery of chemotherapeutic agents and also for the efficacy of radiation therapy that is oxygen-dependent. The broad long-term objectives of the proposed research are to improve the effectiveness of chemo- and radiation therapies by rectifying key defects in the tumor vasculature. Our recent work has suggested a novel strategy for improving dysfunctional tumor blood vessels with a panel of cytoskeleton-regulating drugs that rectify key defects in neovessels that would otherwise exhibit a pathological phenotype. To apply this new strategy towards improvement of cancer therapies, we propose the following Specific Aims: (1) In mouse models of cancer, employ cytoskeleton-regulating drugs that target Rho GTPase signaling pathways and calpain to rectify important functional defects in the tumor vasculature. Identify combinations of drugs that provide cumulative improvement of tumor vascular perfusion and reduction of hypoxia. (2) Test strategies identified in Aim 1 that maximally increase tumor vascular perfusion and increased tumor oxygenation for improved delivery and efficacy of representative chemotherapeutic agents and improved tumor radiotherapy. Experiments in Aim 1 will define the specific contributions of the various cytoskeleton-regulating drugs, identified in our preliminary studies, to enhance perfusion and oxygenation of important representative tumors and define the optimal dose response and time course for such alterations. Parameters to be measured are improvement of angio-architecture, improved blood flow, increased tumor perfusion, and reduced hypoxia. Depending on findings with each drug individually, we will conduct experiments with combinations of these drugs designed to achieve maximal improvement of tumor perfusion and oxygenation. Experiments in Aim 2 will test the efficacy of the optimal tumor vessel rectifying strategies identified in Aim 1 for improving tumor perfusion and tumor killing using representative chemotherapeutic agents. Experiments in Aim 2 also will test optimal strategies identified in Aim 1 that reduce tumor hypoxia for improved radiation therapy. Validation of this strategy in the proposed preclinical studies offers the prospect of rapid improvement in conventional chemo- and radiation therapies for cancer patients. This is because the several classes of drugs to be used here for stable normalization of pathological tumor blood vessels are actively being pursued as potential therapeutics for other disorders. Thus, implementation of this strategy would not require the extended time and expense typically associated with new drug development. PUBLIC HEALTH RELEVANCE: The goals of this research are to identify and develop new strategies for improving conventional cancer therapies. The blood vessels of tumors are highly abnormal, resulting in poor delivery of chemotherapeutic agents and impaired sensitivity to radiation therapy. Our proposed strategy is to achieve drug-mediated correction of these blood vessel defects in order to increase effectiveness of chemo- and radiation therapies and thereby improve cancer patient survival.

描述（由申请人提供）：实体瘤的血管系统高度缺陷，导致血流不畅和缺氧。这些缺陷对于化疗剂的递送以及对于氧依赖性的放射疗法的功效具有深刻的负面后果。拟议研究的广泛长期目标是通过纠正肿瘤血管系统中的关键缺陷来提高化疗和放疗的有效性。我们最近的工作提出了一种新的策略，用于改善功能失调的肿瘤血管与一组细胞因子调节药物，纠正新血管中的关键缺陷，否则将表现出病理表型。为了将这种新策略应用于改善癌症治疗，我们提出了以下具体目标：（1）在小鼠癌症模型中，采用靶向Rho GT3信号通路和钙蛋白酶的细胞因子调节药物来纠正肿瘤血管系统中的重要功能缺陷。确定药物组合，提供肿瘤血管灌注的累积改善和缺氧的减少。(2)在目标1中确定的测试策略，其最大限度地增加肿瘤血管灌注和增加肿瘤氧合，以改善代表性化疗剂的递送和功效以及改善肿瘤放疗。目标1中的实验将定义在我们的初步研究中确定的各种细胞因子调节药物的具体贡献，以增强重要代表性肿瘤的灌注和氧合，并定义这种改变的最佳剂量反应和时间过程。待测量的参数是血管结构的改善、血流的改善、肿瘤灌注的增加和缺氧的减少。根据每种药物单独的发现，我们将进行这些药物组合的实验，以实现肿瘤灌注和氧合的最大改善。目标2中的实验将测试目标1中确定的最佳肿瘤血管矫正策略使用代表性化疗剂改善肿瘤灌注和肿瘤杀伤的功效。目标2中的实验还将测试目标1中确定的减少肿瘤缺氧以改善放射治疗的最佳策略。在临床前研究中验证这一策略提供了快速改善癌症患者常规化疗和放疗的前景。这是因为在此用于病理肿瘤血管稳定正常化的几类药物正被积极地作为其他疾病的潜在治疗剂。因此，该策略的实施将不需要通常与新药开发相关的延长的时间和费用。公共卫生相关性：本研究的目标是确定和开发改进传统癌症治疗的新策略。肿瘤的血管是高度异常的，导致化疗剂的不良递送和对放射治疗的敏感性受损。我们提出的策略是实现药物介导的纠正这些血管缺陷，以提高化疗和放疗的有效性，从而提高癌症患者的生存率。